Transaction DateRecipientSharesTypePriceValue
1st September 2020Inc. Innoviva,4,672,897Open or private purchase$2.68$12,499,999.48
11th June 2020Inc. Innoviva,12,677,490Open or private purchase$2.50$31,693,725.00
27th March 2020Inc. Innoviva,7,717,661Open or private purchase$2.87$22,149,687.07
4th February 2020Life Sciences Viii, L.P. Frazier6,360,272Conversion of derivative$0.00
4th February 2020Life Sciences Viii, L.P. Frazier2,099,019Conversion of derivative$0.00
4th February 2020Life Sciences Viii, L.P. Frazier1,074,467Conversion of derivative$0.00
4th February 2020Life Sciences Viii, L.P. Frazier500,000Open or private purchase$17.00$8,500,000.00
9th January 2020Life Sciences Viii, L.P. Frazier50,000Open or private sale$5.00$250,010.00
18th January 2019Life Sciences Viii, L.P. Frazier372,439Open or private purchase$5.37$1,999,997.43
Entasis Therapeutics Holdings
Entasis Therapeutics Holdings logo

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections.

Ticker: ETTX
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1724344
Employees: 33
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals